FDA rebuff for Keytruda in breast cancer indication

A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the companyâs application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.